Therapeutic area intelligence for Diagnostic Imaging with 4 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 4
Catalysts: 0
Companies: 1

Companies

IC-GREEN →

Assets

FDA →

Recent signals(4)

RegulatoryAugust 8, 2026

FDA Grants Approval for Indocyanine Green by Zydus Lifesciences

The FDA has granted approval for the Abbreviated New Drug Application (ANDA) 219139 for Indocyanine Green submitted by Zydus Lifesciences.

RegulatoryJuly 28, 2026

FDA Accepts Supplement for Indocyanine Green by Renew Pharms

The FDA has accepted a supplemental application for Indocyanine Green (NDA011525) from Renew Pharms.

Regulatory

July 5, 2026

FDA Accepts Supplement Application for IC-GREEN by RENEW PHARMS

The FDA has accepted a supplemental application for IC-GREEN, an imaging agent containing Indocyanine Green, submitted by RENEW PHARMS.

CompetitiveJune 28, 2026

Trial on Computerized Tool for Faster Brain Scan Diagnosis Initiated

A trial is underway to evaluate the effectiveness of a computerized tool (MIDI) in diagnosing brain scan issues more quickly.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

No related entities indexed yet.

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.